News
Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...
Lundbeck’s Vyepti (eptinezumab) has met both the primary and secondary endpoints in the placebo-controlled Phase IV ...
Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results